NBSE News and Press, NeuBase Therapeutics Inc. From 09/24/19

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

PITTSBURGH, Sept. 09, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that it will host a Key Opin...

This article is part of a series that provides an ongoing analysis of the changes made to David Einhorn's Greenlight Capital 13F portfolio on a quarterly basis. It is based on Einhorn's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking David Einhorn's Greenlight Capital Hol...

NeuBase Therapeutics (NASDAQ: NBSE ): Q3 GAAP EPS of -$0.40. More news on: NeuBase Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Completed two financings in July 2019 totaling approximately $14 million in gross proceeds with participation from institutional investors including Greenlight Capital                PITTSBURGH, Aug. 14, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeut...

PITTSBURGH, Aug. 07, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that its chairman and chief ...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) declined again last week, falling from 3,323.71 points on Monday’s (July 29) open to 3,282.81 points as of 1:22 p.m. EDT on Friday (August 2). Over the course of the week, a number of top companies released pivotal Q2 2019 earnings, i...

PITTSBURGH, July 30, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the addition of Samuel Broder...